Abstract
This study, which included 153 heart transplant patients, was designed to determine whether the cytomegalovirus (CMV) status of both donor and recipient may influence graft rejection. The follow-up was 1 year and they all received the same triple-drug immunosuppressive regimen with induction (antilymphocyte serum). There was no difference in the total rejection rate, but an increase in repeated rejection rate was shown in transplant recipients with hearts from CMV seropositive donors (P < 0.05). These data strongly suggest the impact of CMV in enhancement but not in induction of rejection. To prevent iterative rejection in the CMV seropositive donor group, antiviral therapy could be proposed during enhancement of antirejection therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Reference
The International Society for Heart Transplantation, Billingham ME, Cary NR, Hammond ME,(1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung transplantation: Heart Rejection Study Group. J Heart Transplant 9: 587–593
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Decoene, C. et al. (1996). Relationship between CMV and graft rejection after heart transplantation. In: Mühlbacher, F., et al. Transplant International . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00818-8_62
Download citation
DOI: https://doi.org/10.1007/978-3-662-00818-8_62
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-61024-3
Online ISBN: 978-3-662-00818-8
eBook Packages: Springer Book Archive